Potential Addition to the Amarantus Portfolio
Post# of 30067
Posted On: 11/18/2014 9:42:30 PM
Potential Addition to the Amarantus Portfolio
Quote:
"Dr. Lowe’s advisory firm, NeuroAssets, Sarl, will be overseeing the translational development of MANF through first-in-man clinical studies, as well as advise on development of the LymPro Test Blood Diagnostic for Alzheimer’s disease, PhenoGuard Protein Discovery Engine, and potential addition to the Amarantus portfolio." - Gerald Commissiong - 11/18/2013 Conference Call
Quote:
"We also expect to bolster our pipeline with a clinical stage in-licensing transaction that management believes will attract 'institutional investors to the Company." Gerald Commissiong January 17, 2014
http://www.thechairmansblog.com/amarantus-bio...ting-2014/
Quote:
18.) potential - new acquisition / Cerora AD scanner
http://investorshangout.com/post/view?id=2160389
(0)
(0)